Bangalore, January 20, 2006
Revenues Rs. 578 crs: EBITDA Rs.173 crs: PAT Rs. 126 crs
Biocon Limited today announced its financial performance for the nine months ended December 31, 2005.
Note : The discussions in this release reflect the audited financial performance of Biocon Limited based on Indian GAAP on a consolidated basis. This considers the financial performance of Biocon Limited, its wholly owned subsidiaries Syngene International Private Limited and Clinigene International Private Limited and its 51% joint venture Biocon Biopharmaceuticals Private Limited.
PERFORMANCE HIGHLIGHTS - 9 MONTHS FY06
Consolidated Sales grew by 7% over the same period in the previous year.Operating profits (EBITDA) fell by 7%. Profit after Tax margins are at a healthy 22%.
Operating results continue to be challenged by the difficult pricing environment in the European Statins market. However, the US market for generic Statins offer respite in 2006-07.
Research Services, Insulin and other pharmaceutical products performed strongly.
Biocon's discovery led Diabetes and Oncology research programs are making good progress.
Dedicated Sales Organisation established for Oncology Products
Commenting on the results, Kiran Mazumdar-Shaw, Chairman & Managing Director, Biocon Limited , said:
"I am pleased that we continue to deliver healthy profits at a time when we are investing in our discovery led research programs. Operating (EBITDA) margins of 30% demonstrate the quality and spread of our various businesses. We are excited with the progress being made on the research and development front as we believe that we are creating powerful innovation platforms for our future. We are now building domain knowledge in both Oncology and Diabetes which are the focal points of our discovery led research programs. This research combined with our manufacturing expertise reinforces our integrated bio-pharmaceutical model"
2nd SCIENTIFIC ADVISORY BOARD:
The tenure of the First SAB came to an end on 31st December, 2005. The company has constituted the Second SAB as follows:
Prof. Charles L. Cooney, Department of Chemical and Biochemical Engineering, MIT, US
Dr. Bala S. Manian, Reametrix Inc., USA and India
Dr. Anthony Allison, Alavita Pharmaceuticals Inc., USA
Dr. Hans Wigzell, Karolinska Institute, Sweden
Dr. Chaitanya R. Divgi, Memorial Sloan-Kettering Cancer Center, USA
Dr. Kiran Mazumdar-Shaw, Biocon Limited, India
Established in 1978, Biocon Limited is one of India's premier biotechnology companies. Biocon and its two subsidiary companies, Syngene International Ltd and Clinigene International Ltd form a fully integrated biotechnology enterprise, specializing in biopharmaceuticals, custom research, clinical research and enzymes. With successful initiatives in clinical development, bio-processing and global marketing, Biocon delivers products and solutions to partners and customers across the Globe. Visit us at www.biocon.com
Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking statements. Important factors that could cause actual results to differ materially from our expectations include, amongst others general economic and business conditions in India, our ability to successfully implement our strategy, our research and development efforts, our growth and expansion plans and technological changes, changes in the value of the Rupee and other currency changes, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global biotechnology and pharmaceuticals industries, increasing competition in and the conditions of the Indian biotechnology and pharmaceuticals industries, changes in political conditions in India and changes in the foreign exchange control regulations in India. Neither our Company, nor our Directors, or any of their respective affiliates have any obligation to update or otherwise revise any statements reflecting circumstances arising after this date or to reflect the occurrence of underlying events, even if the underlying assumptions do not come to fruition.